YAP inhibition was obtained with statin, effectively prolonging survival among lung cancer patients, corroborating the effectiveness of co-targeting EGFR and YAP as a therapeutic strategy through TKI-resistance development delay [23]. This evidence concerns the gene YAP1 and lung cancer.